ライフサイエンスコーパス: screening for

1 tography-tandem mass spectrometry (LC-MS/MS) screening for 23 classes of PFASs, followed by quantitat

2 Annual CT lung screening for 3 years beginning at age 50 years.

3 Genetic screening for a germline mutation at the RET gene was pe

4 me available allowing rapid expanded carrier screening for a substantial number of conditions.

5 c cerebrospinal fluid (CSF) specimens during screening for a trial on the treatment of HIV-associated

6 these principles: the 2015 recommendation on screening for abnormal blood glucose and type 2 diabetes

7 An important consideration is whether screening for abnormal glucose levels or diabetes reduce

8 Screening for activators capable of synergizing with HMG

9 In nonhealthcare settings, widespread screening for acute human immunodeficiency virus (HIV) i

10 d activators of GAC, which should facilitate screening for additional modulators of this important me

11 endeavor that may be facilitated by newborn screening for adrenoleukodystrophy.

12 cell technology to generate human cells for screening for adverse effects of drugs in humans.

13 Screening for AFC should be performed even in the absenc

14 potential applications in modeling and drug screening for airway diseases.

15 ed selection for CT lung screening, assuming screening for all ever-smokers, yield the percent change

16 esults highlight the need for general vision screenings for all children prior to school entry given

17 utant was isolated through a forward genetic screening for altered expression of the luciferase repor

18 a is important for the cost-effectiveness of screening for amblyopia (lazy eye, prevalence 3-3.5 %).

19 rvices Task Force (USPSTF) recommendation on screening for amblyopia and its risk factors in children

20 free and affordable tools provide sensitive screening for amblyopia in children from public, private

21 Delays in screening for and assessing dysphagia after stroke, are

22 ients at high risk for T2D and to coordinate screening for and diagnosis of prediabetes and T2D.

23 it is proven, then the cost-effectiveness of screening for and the treatment of subclinical AF will r

24 To review the evidence on screening for and treatment of amblyopia, its risk facto

25 ed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21

26 s designed to determine definitively whether screening for and treatment of M. genitalium infections

27 ant immunizations; and the possible harms of screening for and treatment of mild to moderate COPD.

28 e is adequate evidence to bound the harms of screening for and treatment of preeclampsia as no greate

29 Diagnostic screening for Anderson-Fabry cardiomyopathy (AFC) is per

30 re, we present two advances towards low-cost screening for anemia.

31 We tested the hypothesis by screening for antagonism among all possible pairwise int

32 Screening for anti-RrgA monoclonal antibodies specifical

33 In addition, regular screening for antibiotic resistance would improve correc

34 nce of incorporating 3D mechanical cues into screening for anticancer drugs.

35 has a wide range of applications, including screening for antiseizure agents and identifying channel

36 ccessful 2005 congressional campaign to fund screening for aortic aneurysms brought the disease to na

37 We established high-throughput screening for assembly inhibitors based on competition o

38 e (USPSTF) published a clinical guideline on screening for asymptomatic carotid artery stenosis.

39 As a result, the ACP recommended against screening for asymptomatic patients who are at low risk

40 influenza virus with a rapid high-throughput screening for attenuation to generate W7-791, a live att

41 Screening for Barrett's esophagus (BE), the only known p

42 atform for the fast and efficient functional screening for bioactive compounds in complex natural mix

43 ication based on SSU gene sequences prior to screening for bioactive molecules can miss potentially i

44 pounds, followed by in silico refinement and screening for biological activity in vitro, we identifie

45 October 31, 2014, in whom routine serologic screening for Borrelia burgdorferi (IgG as determined by

46 d were similar for triennial versus biennial screening for both age groups (50 to 74 years, median of

47 e significantly associated with older age at screening for both urban and rural women; additionally,

48 Biennial screening for breast cancer is efficient for average-ris

49 balance of benefits and harms of adjunctive screening for breast cancer using breast ultrasonography

50 Compared with population-based screening for breast cancer with annual CBE, universal b

51 type 2 diabetes; the 2016 recommendation on screening for breast cancer; and the recommendation on s

52 Young women were very amenable to home screening for BV, gonorrhea, and chlamydia.

53 Selective use of screening for CAC might be considered in individuals wit

54 ability to benefit from ctDNA, starting with screening for cancer before it is clinically apparent.

55 Screening for cancer in patients with unprovoked venous

56 precluded their routine use in monitoring or screening for cancer.

57 pportunities in tissue-based pharmacological screening for cardiac and neuronal diseases as well as f

58 iscussants address the risks and benefits of screening for carotid artery disease as well as how to a

59 Conclusions and Relevance: Newborn screening for cCMV infection appears to be cost-effectiv

60 review the evidence on benefits and harms of screening for celiac disease in asymptomatic adults, ado

61 y questions related to benefits and harms of screening for celiac disease in asymptomatic individuals

62 assess the balance of benefits and harms of screening for celiac disease in asymptomatic persons.

63 Therefore, screening for celiac disease must occur before a gluten-

64 inical benefits and harms of screening vs no screening for celiac disease or treatment vs no treatmen

65 No trials of screening for celiac disease were identified.

66 found inadequate evidence on the accuracy of screening for celiac disease, the potential benefits and

67 rvices Task Force (USPSTF) recommendation on screening for celiac disease.

68 cally validate HPV assays for use in primary screening for cervical cancer and also provide a framewo

69 the USPSTF already recommends screening (ie, screening for cervical cancer with a Papanicolaou smear,

70 s including vaccination coverage, changes in screening for cervical cancer, and risk behaviors for ac

71 INTERPRETATION: Screening for Chagas disease in asymptomatic Latin Ameri

72 invasion assays, proving the AHTM capable of screening for changes in mechanical phenotype.

73 European Union suggest the need for improved screening for chemical disruption to endocrine systems a

74 Academy of Ophthalmology recommendations on screening for chloroquine (CQ) and hydroxychloroquine (H

75 We believe that early screening for ciliary body cysts is important in patient

76 Screening for CKD should be considered before and during

77 Future studies should explore routine screening for clinical frailty in critically ill patient

78 In screening for collagen substrate sites for the remaining

79 Screening for colonization on admission could limit risk

80 he USPSTF concludes with high certainty that screening for colorectal cancer in average-risk, asympto

81 The USPSTF recommends screening for colorectal cancer starting at age 50 years

82 aly, were randomly assigned to be invited to screening for colorectal cancer with FS or CT colonograp

83 ning questionnaires and spirometry); whether screening for COPD improves the delivery and uptake of t

84 The USPSTF reviewed the evidence on whether screening for COPD in asymptomatic adults (those who do

85 The USPSTF recommends against screening for COPD in asymptomatic adults.

86 2008, the USPSTF did not find evidence that screening for COPD in asymptomatic persons improves heal

87 ny logistical concerns in providing toxicity screening for copious new materials.

88 Netherlands who were offered 4 rounds of FIT screening for CRC from November 2006 through December 20

89 ementation of mandatory policies for newborn screening for critical congenital heart disease was asso

90 The development of mSIBA enables rapid screening for CT and NG within point-of-care or central

91 deration must be given to universal neonatal screening for cytomegalovirus to facilitate early detect

92 aria compared to algorithms that incorporate screening for danger signs.

93 Using RNAi screening for defects in Caenorhabditis elegans anchor c

94 rvices Task Force (USPSTF) recommendation on screening for depression in adults.

95 Screening for desired clones with CRISPR-mediated genomi

96 he increasing prevalence of diabetes, annual screening for diabetic retinopathy (DR) by expert human

97 Screening for diabetic retinopathy every 2.5 years is co

98 r 5 years, current recommendations regarding screening for diabetic retinopathy include annual dilate

99 latter helps us to facilitate small molecule screening for differentiation efficiency.

100 Screening for DMD will result in identification of other

101 The mean rate of screening for DR before implementation of the program wa

102 of Ophthalmology recommends that ophthalmic screening for DR occur beginning at 5 years after initia

103 onitors p53 sumoylation status and expedites screening for drugs that enhance p53 sumoylation would b

104 Estimating the potential effects of screening for dyslipidemia in this population requires e

105 Bedside screening for dysphagia was performed within 3 hours aft

106 mportant layer of functional regulation, but screening for E3 ligase-substrate interactions is time-c

107 These findings have prompted screening for EBF1-PDGFRB in patients entered onto the c

108 omarkers is of utmost importance in clinical screening for effective identification and treatment of

109 BACKGROUND/Universal screening for elder abuse and neglect is a current contr

110 estimates, the simulated diagnostic yield of screening for elevated TC varies between 4.8% and 12.3%

111 Screening for enhancers of ABT-199 sensitivity in MYCN-a

112 However, systematic screening for epigenetic regulators is challenging and o

113 proof of recent ZIKV infection and negative screening for etiologies of GBS.

114 We sought to assess the interest of screening for extended-spectrum beta-lactamase-producing

115 Screening for extended-spectrum beta-lactamase-producing

116 of the NHANES as a model of population-based screening for eye disease, FDT perimetry lacks both sens

117 ophthalmologist is essential, especially in screening for eyelid and ocular surface tumors.

118 eported a whole-genome small interfering RNA screening for factors involved in HIV that identified RN

119 Child-parent screening for familial hypercholesterolemia has been pro

120 lar disease in a primary prevention patient; screening for familial lipid disorders in a patient with

121 Screening for femoral plaques may be an appealing strate

122 = 83,241), the diagnostic yield of universal screening for FH in childhood is 1.3 to 4.8 cases per 10

123 There is no evidence for the effect of screening for FH in childhood on lipid concentrations or

124 argeting osteoporosis and related fractures, screening for fracture risk is not currently advocated i

125 s demonstrate the utility of high-throughput screening for functional characterization of noncoding D

126 High-throughput screening for functional targets reveals that each miRNA

127 Thus, screening for FVIII-specific IgG could be beneficial in

128 for basic discovery and high-throughput drug screening for G-protein-coupled receptors and ion channe

129 ic compared with NK cytotoxicity testing for screening for genetic HLH and should be considered for a

130 , we argue for routine, early and cumulative screening for genetic predictors of efficacy, as an inte

131 Conclusions and Relevance: Serologic screening for genital herpes is associated with a high r

132 Serologic screening for genital herpes was associated with psychos

133 USPSTF recommends against routine serologic screening for genital HSV infection in asymptomatic adol

134 the harms outweigh the benefits of serologic screening for genital HSV infection in asymptomatic adol

135 th sensitivity and specificity as a means of screening for glaucoma, the presence of retinal disease,

136 d their eye screened with just a few (4.3 %) screening for glaucoma.

137 r cervical cancer with a Papanicolaou smear, screening for gonorrhea and chlamydia).

138 rvices Task Force (USPSTF) recommendation on screening for gynecologic conditions with pelvic examina

139 t clinical applications, such as noninvasive screening for HCC in populations where viral hepatitis a

140 ents with cirrhosis who underwent ultrasound screening for HCC.

141 Implementation of the Baby Boomer Screening for HCV requires identifying screening environ

142 Screening for hepatic encephalopathy (HE) that does not

143 Hence, it is necessary to do diagnostic screening for high-risk HBV patients in these transmissi

144 ing incidence of infection and the effect of screening for HIV in general practices in Hackney.

145 INTERPRETATION: Screening for HIV in primary care has important public h

146 Screening for HIV in primary care is cost-effective and

147 HIV infection should be targeted for regular screening for HIV-associate neurocognitive disorder, par

148 e counseling regarding lifestyle and undergo screening for hormonal deficits to minimize the risk of

149 In screening for host factors that interact with HIV-1 MA,

150 metabolism, can be detected through newborn screening for hyperphenylalaninemia (HPA).

151 He was offered screening for hypothalamic-pituitary axis (HPA) dysfunct

152 Screening for iciHHV-6 could guide donor selection and p

153 assess the balance of benefits and harms of screening for impaired visual acuity in older adults.

154 4728) from the 2009 USPSTF review found that screening for impaired visual acuity was not associated

155 older adults in primary care settings vs no screening for improving visual acuity or other clinical

156 Outcomes assessed for the most recent screening for individual women undergoing only 1, 2, or

157 tified Arabidopsis pex6 and pex26 mutants by screening for inefficient seedling beta-oxidation phenot

158 and should prove useful for high-throughput screening for inhibitors of PSD enzymes across diverse p

159 he fluorogenic probe permits high-throughput screening for inhibitors that may hold promise as treatm

160 Screening for initial disease and progression will likel

161 Although the clinical benefit of screening for intracranial aneurysm in patients with FMD

162 upplementation for pregnant women or routine screening for iron deficiency anemia in pregnant women o

163 a rapid, easy to use means for point-of-care screening for iron deficiency in resource-limited settin

164 ine (ABMA) from a cell-based high throughput screening for its capacity to protect human cells and mi

165 Periodic patient screening for K. pneumoniae colonization has the potenti

166 hermophoresis (MST) is a valuable method for screening for ligands and binding partners of even such

167 This approach consists of screening for likely dominant T-cell epitopes, establish

168 rvices Task Force (USPSTF) recommendation on screening for lipid disorders in adults.

169 These data suggest that programmes of screening for liver fibrosis in the general population s

170 entified and could be used to decide whether screening for long-term carriage (e.g., in health care w

171 The USPSTF reviewed the evidence on screening for LTBI in asymptomatic adults seen in primar

172 rs, application of a risk-based model for CT screening for lung cancer compared with a model based on

173 Annual low-dose CT screening for lung cancer has been recommended for high-

174 Screening for lung cancer with low-dose computed tomogra

175 rom 2 prospective studies of the efficacy of screening for Lynch syndrome, we identified patients wit

176 Ts) are becoming available, and their use in screening for M. genitalium has been advocated, but M. g

177 Combined screening for m/z 130.1 along with side chain-specific J

178 matopoietic stem cells to facilitate genetic screening for malaria host factors.

179 Scheduled screening for malaria parasites with the current generat

180 assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger.

181 Large-scale screening for melanoma within a United States health car

182 INTERPRETATION: Post-deployment screening for mental disorders based on tailored advice

183 The effectiveness of post-deployment screening for mental disorders has not been assessed in

184 as drug resistant, prompting hospital-based screening for methicillin-resistant S. aureus and implem

185 Therefore, COX18 is a new candidate when screening for mitochondrial disorders associated with is

186 g, which provides a highly accurate means of screening for MMR-D in the same assay that is used for t

187 methods include comprehensive combinational screening for (mutant) RNA in prostasomes that are immun

188 valuated by clinical examination and genomic screening for mutations in SCN9A and SCN11A.

189 Finally, screening for Myb-binding sites in the candidate gene pr

190 Three-site genital and extragenital screening for Mycoplasma genitalium in 102 asymptomatic

191 Natural product screening for new bioactive compounds can greatly benefi

192 hes have hindered systematic forward genetic screening for NMD factors in human cells.

193 s) that enables CRISPR-based forward genetic screening for NMD pathway defects in human cells.

194 results may help pave the way for widespread screening for nutritional and genetic anemias.

195 rvices Task Force (USPSTF) recommendation on screening for obesity in children 6 years and older.

196 SPSTF concluded with moderate certainty that screening for obesity in children and adolescents 6 year

197 The USPSTF reviewed the evidence on screening for obesity in children and adolescents and th

198 Here, we performed a dominant screening for obesity using C57BL/6 substrains, C57BL/6J

199 to March 12, 2015, supplemented with manual screening for observational studies assessing the associ

200 isplay and hybridoma platforms by functional screening for opsonophagocytic killing activity.

201 purposes including gene knock-out libraries, screening for optimal integration positions or safe geno

202 cohort studies; and case-control studies on screening for or treatment of asymptomatic dyslipidemia

203 The USPSTF found insufficient evidence on screening for or treatment of OSA in asymptomatic adults

204 e accuracy, benefits, and potential harms of screening for OSA in asymptomatic adults seen in primary

205 rvices Task Force (USPSTF) recommendation on screening for OSA in asymptomatic adults.

206 assess the balance of benefits and harms of screening for OSA in asymptomatic adults.

207 ne the magnitude of the benefits or harms of screening for OSA or whether there is a net benefit or h

208 ment were ascertained: follow-up mammograms, screening for other cancers, general preventive care, an

209 In recent years, screening for p53 activators and a better understanding

210 Whether low PC counts are useful in screening for PAD needs to be investigated.

211 ly time-consuming and have a narrow focus on screening for particular microorganism species.

212 ompted primary care providers to perform HCV screening for patients seen in primary care clinic (1) b

213 the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on

214 To evaluate telemedicine retinal screenings for patients with type 1 or 2 diabetes and id

215 About 50% were aware of the need for eye screening for people with the complications.

216 We performed whole-genome screenings for phylogenetically diagnostic retrotranspos

217 or the future development of high-throughput screening for plant phenotyping and the quantification o

218 We aimed to assess whether post-deployment screening for post-traumatic stress disorder (PTSD), dep

219 significantly associated with poor outcomes, screening for posttransplant anxiety should also be rout

220 ied additional host WW-domain interactors by screening for potential interactions between mammalian p

221 In a screening for potential monoamine oxidase A and B inhibi

222 and improves access was developed to improve screening for potentially blinding conditions.

223 The USPSTF recommends screening for preeclampsia in pregnant women with blood

224 y that there is a substantial net benefit of screening for preeclampsia in pregnant women.

225 nts, the USPSTF found adequate evidence that screening for preeclampsia results in a substantial bene

226 lampsia, the potential benefits and harms of screening for preeclampsia, the effectiveness of risk pr

227 rvices Task Force (USPSTF) recommendation on screening for preeclampsia.

228 Screening for primary aldosteronism should nonetheless b

229 potential usefulness as a method for rapidly screening for prohibited substances in on-site/in vivo s

230 imates from the European Randomized Study of Screening for Prostate Cancer after 9-13 years.

231 g trial and the European Randomized Study of Screening for Prostate Cancer has been inconsistent, due

232 These data strongly suggest that PSA screening for prostate cancer may be more harmful than p

233 139 men from the Finnish Randomized Study of Screening for Prostate Cancer were analyzed.

234 The ERSPC (European Randomized Study of Screening for Prostate Cancer) found that screening redu

235 for breast cancer; and the recommendation on screening for prostate cancer, which is currently in pro

236 nded against prostate-specific antigen (PSA) screening for prostate cancer.

237 In screening for proteins that interact with ASK1 in the co

238 ienced GBV were identified through community screening for psychological distress and impaired functi

239 nopelvic CT in trauma centers, opportunistic screening for radiologic indicators of frailty provides

240 venience of using RGM medium enables routine screening for rapidly growing NTM in all submitted sputu

241 IV testing are more effective than universal screening for reaching young sexual minority males (espe

242 HNC) treatment, focusing on surveillance and screening for recurrence or second primary cancers, asse

243 Screening for recurrently mutated genes in the mononucle

244 Vision screening for refractive error and related eye diseases

245 aging models and during development, and (4) screening for regulators of muscle mitochondrial dynamic

246 hybridization, and polymerase chain reaction screening for relevant abnormalities were centrally revi

247 d to a tertiary ophthalmology hospital after screening for retinopathy in 2012 were eligible for incl

248 or poor follow-up of diabetic patients after screening for retinopathy in Kilimanjaro Region of Tanza

249 -eight percent of patients underwent regular screening for retinopathy, 47.1% for nephropathy, 4.5% f

250 Screening for right ventricular dysfunction using goal-d

251 Screening for RVs before HCT might identify patients at

252 ges faced by families as a result of genetic screening for SADS to enable equitable access to insuran

253 a for SCID, and the pilot project of newborn screening for SCID in the Navajo Nation.

254 cellular tool to facilitate therapeutic drug screening for severe neurodevelopmental disorders.

255 imit the scope and sustainability of newborn screening for sickle cell disease (SCD) in sub-Saharan A

256 analyses, these approaches may enhance early screening for sickle retinopathy.

257 Evidence to assess the net benefit of screening for skin cancer with a clinical visual skin ex

258 Screening for small molecules or drugs that can protect

259 the Patient Health Questionnaire-15 and the Screening for Somatoform Symptoms Conversion Disorder su

260 cohort noninferiority study of urine protein screening for specific indications compared with routine

261 Recent advances include systematic universal screening for stroke risk, improved management of iron o

262 cific intervention scenarios, which included screening for symptoms, active case finding, and prevent

263 The USPSTF found convincing evidence that screening for syphilis infection in asymptomatic, nonpre

264 The USPSTF reviewed the evidence on screening for syphilis infection in asymptomatic, nonpre

265 The USPSTF recommends screening for syphilis infection in persons who are at i

266 Screening for syphilis infection is currently recommende

267 ase in the percentage of patients undergoing screening for T2D (89 of 283 [31.4%] vs 26 of 282 [9.2%]

268 2 or more risk factors for T2D and underwent screening for T2D.

269 fied mutant variants with intact epitopes by screening for the ability to bind neutralizing anti-ST a

270 us emphasized the applicability of nontarget screening for the assessment of water treatment processe

271 Triennial screening for the average-risk subgroup and annual scree

272 A screening for the BsmI SNP may emphasize the importance

273 Transcriptional screening for the expression G-protein-coupled receptors

274 o received the HPV vaccine are due to attend screening for the first time.

275 nd investigation of the possible benefits of screening for the G6PD genotype along with using HbA1c t

276 ing for the average-risk subgroup and annual screening for the highest-risk subgroup cost less than $

277 By screening for the hydrolase that is responsible for the

278 les for high-throughput applications such as screening for the presence of antibiotic resistant strai

279 ith PLA2R1-associated MN, and more intensive screening for the presence of malignancies may be warran

280 dy, we demonstrate the utility of "admixture screening" for the discovery of new multicomponent heter

281 ller laboratories and may encourage expanded screening for these highly prevalent infections.

282 tients with IA supports the need for routine screening for this sensitivity as a cause of anaphylaxis

283 for women aged 50 to 74 years and selective screening for those aged 40 to 49 years.

284 ed the evidence on the benefits and harms of screening for thyroid cancer in asymptomatic adults, the

285 The USPSTF recommends against screening for thyroid cancer in asymptomatic adults.

286 therefore determined that the net benefit of screening for thyroid cancer is negative.

287 rvices Task Force (USPSTF) recommendation on screening for thyroid cancer.

288 evidence was inadequate to determine whether screening for thyroid dysfunction reduced cardiovascular

289 the way for the implementation of universal screening for toxoplasmosis infection during gestation.

290 Symptom-based screening for tuberculosis is recommended for all people

291 luding routine voluntary testing for HIV and screening for tuberculosis upon entry to South African a

292 ly, reverse transcription PCR (RT-PCR)-based screening for two specific RNA bacteriophages in stool s

293 rs, presentation, optimal management of, and screening for urologic malignancies in kidney transplant

294 laced on scenarios that offer less intensive screening for vaccinated women and more on increasing co

295 jected it to random mutagenesis, followed by screening for variants whose in vivo folding displays in

296 We recommend that screening for VGKCC, LGI1 and Caspr2 antibodies be consi

297 The USPSTF reviewed the evidence on screening for visual acuity impairment associated with u

298 fficient to assess the benefits and harms of screening for vitamin D deficiency in asymptomatic adult

299 well as the challenges and controversies, of screening for vitamin D deficiency in primary care pract

300 Task Force recommended biennial mammography screening for women aged 50 to 74 years and selective sc